Kinpeygo (Budesonide)

Budesonide binds to glucocorticoid receptors inside cells, influencing gene transcription. This results in decreased production of inflammatory cytokines, reduced leukocyte migration, and stabilization of cell membranes, providing potent anti‑inflammatory and immunosuppressive effects within the gastrointestinal tract.

The dosage of Kinpeygo is determined by the prescribing physician based on the severity of the disease, patient weight, and response to therapy. Only a qualified healthcare professional should set the appropriate dose and treatment schedule.

Safety data for budesonide in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant. Physicians should discuss individual circumstances with the patient before prescribing.

To request Kinpeygo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with systemic corticosteroids, budesonide offers high topical activity with lower systemic exposure, reducing the risk of classic steroid side effects. It is often preferred for mild‑to‑moderate disease when a targeted anti‑inflammatory effect is desired, while biologics provide deeper immunomodulation for refractory cases.

Kinpeygo should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight to maintain its stability throughout its shelf life.

Kinpeygo is taken orally as directed by the prescriber, usually with water. The tablets (or capsules) should be swallowed whole and not crushed or chewed unless the label specifically permits it.

Serious risks include adrenal suppression, severe infections, and hypersensitivity reactions. Patients should be monitored for signs of these events, especially during long‑term therapy or when using high doses.

Kinpeygo is contraindicated in patients with known hypersensitivity to budesonide or any excipients, and it should be avoided in individuals with active, uncontrolled systemic infections. Caution is also advised for patients with severe osteoporosis or uncontrolled diabetes.